Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk

Prior research has shown that patients undergoing Percutaneous Coronary Intervention (PCI) require careful pharmacological management to prevent stent thrombosis while minimizing hemorrhagic complications. Clinical guidelines traditionally recommended prolonged dual antiplatelet regimens to mitigate the risk of myocardial infarction and other ischemic events following the placement of drug-eluting stents. However, the emergence of high bleeding risk phenotypes necessitated a reevaluation of these standard protocols to protect vulnerable individuals from life-threatening bleeding episodes. While shortened regimens appeared effective in general populations, the specific physiological challenges posed by metabolic disorders like diabetes mellitus remained poorly understood in this context. Patients with diabetes often exhibit heightened platelet reactivity and accelerated atherosclerosis, potentially complicating the transition to shorter therapeutic durations. The interaction between metabolic dysfunction and the healing process of coronary vessels after stenting requires precise clinical evidence to avoid adverse outcomes. This absence of evidence motivated a rigorous investigation into whether the benefits of reduced treatment duration extend to those with concurrent diabetic conditions.

This investigation evaluated the comparative effectiveness of a one-month abbreviated antiplatelet regimen against a standard three-month or longer protocol in high-risk patients. Researchers specifically targeted individuals categorized as having a High Bleeding Risk (HBR) who also required biodegradable polymer sirolimus-eluting coronary stent implantation. The analysis sought to determine if the presence of diabetes mellitus altered the safety profile or the efficacy of reducing the duration of antiplatelet administration. By examining a large cohort, the study aimed to clarify whether the increased ischemic risk inherent to diabetic patients precludes the use of shortened therapy. The team focused on measuring net adverse clinical events and major adverse cardiac or cerebral events to ensure comprehensive safety monitoring. They also prioritized the assessment of bleeding complications to determine if the abbreviated strategy provided a significant safety advantage. Establishing a clear evidence base for this subgroup helps clinicians tailor post-procedural care to the specific needs of diabetic patients without compromising their vascular health.

The research team conducted a prespecified analysis of the MASTER DAPT trial, which utilized a randomized controlled design to compare different treatment durations. A total of 4,579 participants identified as having a High Bleeding Risk (HBR) were enrolled, with 1,538 of these individuals diagnosed with diabetes mellitus. Subjects received biodegradable polymer sirolimus-eluting coronary stents before being assigned to either the abbreviated one-month group or the standard group receiving therapy for at least three months. The investigators tracked three primary endpoints over an eleven-month follow-up period to assess clinical success and safety. These endpoints included Net Adverse Clinical Events (NACE), Major Adverse Cardiac or Cerebral Events (MACCE), and the incidence of major or clinically relevant nonmajor bleeding. Net Adverse Clinical Events (NACE) were defined as a composite of all-cause death, myocardial infarction, stroke, and major bleeding episodes. Statistical comparisons utilized hazard ratios and interaction p-values to determine if diabetes status significantly influenced the outcomes of the abbreviated antiplatelet therapy.

Abbreviated antiplatelet therapy demonstrated similar rates of net adverse clinical events and major adverse cardiac or cerebral events compared to the standard regimen regardless of diabetes status. Diabetic patients at high bleeding risk exhibited a significantly higher baseline risk of major adverse cardiac or cerebral events, with a hazard ratio of 1.28 and a 95% confidence interval of 1.00 to 1.63. The study found that the shortened one-month protocol successfully reduced the occurrence of major or clinically relevant nonmajor bleeding in both diabetic and non-diabetic cohorts. Statistical analysis yielded interaction p-values of 0.47 for net adverse clinical events and 0.59 for major adverse cardiac or cerebral events, indicating no significant modification by diabetes. Bleeding reduction remained consistent across groups, supported by an interaction p-value of 0.55, confirming the broad applicability of the abbreviated approach. Despite the higher ischemic burden in the diabetic subgroup, the transition to a one-month regimen did not result in a disproportionate increase in thrombotic complications. These findings indicate that the safety benefits of reduced therapy duration are preserved even in the presence of metabolic comorbidities.

The findings suggest that diabetes mellitus does not necessitate a longer duration of antiplatelet therapy in patients already categorized as having a high bleeding risk. Clinicians can safely implement a one-month abbreviated regimen following the use of biodegradable polymer sirolimus-eluting stents without increasing the risk of major cardiac events. This approach provides an essential strategy for balancing the competing risks of thrombosis and hemorrhage in a population traditionally considered difficult to treat. Future guidelines may incorporate these results to refine the management of diabetic patients who face an elevated danger of bleeding after coronary interventions. The study reinforces the utility of modern stent technologies in enabling shorter pharmacological interventions for complex patient subsets. By demonstrating that diabetes does not modify the treatment effect, the research simplifies the decision-making process for interventional cardiologists. Ongoing research should continue to monitor the long-term outcomes of these abbreviated protocols to ensure sustained cardiovascular stability in diabetic populations.